Skip Navigation

Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations from the Transatlantic Task Force on Antimicrobial Resistance

  1. Joseph Larsen5
  1. 1Division of CBRN Countermeasures, Biomedical Advanced Research and Development Authority, Office of Assistant Secretary for Preparedness ad Response, US Department of Health and Human Services, Washington DC, USA
  2. 2Infection Control and Environmental Health, Norwegian Institute of Public Health, and Institute of Health and Society, University of Oslo
  3. 3Directore General for Health and Food Safety, European Commission, Brussels, Belgium
  4. 4Directorate Health, Directorate-General for Research and Innovation, European Commission, Brussels, Belgium
  5. 5Deputy Director, Biomedical Advanced Research and Development Authority, Office of Assistant Secretary for Preparedness ad Response, US Department of Health and Human Services, Washington DC, USA
  1. Corresponding Author: Joseph Larsen, PhD, Joseph.Larsen{at}hhs.gov, 202-260-0050, BARDA/ASPR/HHS 330 Independence Ave SW (Rm G640), Washington DC 20201

Abstract

The Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) in 2015 was tasked with exploring economic incentives for antibacterial drug development and providing recommendations for potential global implementation. Due to the continual decline of pharmaceutical companies investing in new antibiotic development and the rise in antimicrobial resistance, there is an urgent need to examine market mechanisms that are appropriate to encourage small, medium and large companies to reinvest in this space. This review provides a summary of the various models that have been proposed and highlights positions posed by several policy documents, peer reviewed publications, organization proposals, and government sponsored reviews. The findings support a form of a de-linkage model and a combination of push and pull incentive mechanisms. This level of consensus could culminate in global coordination of incentives that strike a balance of rewarding innovation and ensuring appropriate antibiotic use.

UNCORRECTED PROOF

Published on behalf of

cid cover HIV Medicine Association Logo

Society Members: For your free access to this journal, log in via the IDSA members area.

Impact Factor: 8.886

5-Yr impact factor: 9.206

For Reviewers

Looking for your next opportunity?

Looking for jobs...

For the Media

Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.